Application of Contemporary Neuroproteomic Techniques in Unravelling Neurological Disorders

被引:4
作者
Khurana, Mallika [1 ]
Rahman, Syed Obaidur [2 ]
Najmi, Abul Kalam [2 ]
Pottoo, Faheem Hyder [3 ]
Akhtar, Sayeed [4 ]
机构
[1] Univ Tsukuba, Sch Comprehens Human Sci, Tsukuba Life Sci Innovat, 1 Chome 1-1 Tennodai, Tsukuba, Ibaraki 3058577, Japan
[2] Jamia Hamdard, Sch Pharmaceut Educ & Res, Dept Pharmacol, Pharmaceut Med, New Delhi 110062, India
[3] Imam Abdulrahman Bin Faisal Univ, Coll Clin Pharm, Dept Pharmacol, POB 1982, Dammam 31441, Saudi Arabia
[4] King Khalid Univ, Coll Pharm, Dept Clin Pharm, Abha, Saudi Arabia
关键词
Neuroprotcomic Techniques; neurological Disorders; Alzheimer's disease; Parkinson's disease; multiple sclerosis; epilepsy; psychiatric disorders; Omics; MULTIPLE-SCLEROSIS PATIENTS; QUANTITATIVE PROTEOMIC ANALYSIS; ANTERIOR CINGULATE CORTEX; PLASMA APOLIPOPROTEIN A1; HUMAN SUBSTANTIA-NIGRA; CEREBROSPINAL-FLUID; ALZHEIMERS-DISEASE; PARKINSONS-DISEASE; PSYCHIATRIC-DISORDERS; PROTEIN BIOMARKERS;
D O I
10.2174/1389203721666201104130135
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Decades of research has mimed us with the very distinctive anatomy and physiology of our brain, and on the other hand, its complexity has always posed great difficulty in treating its dysfunction or damage. Understanding the brain under normal and, particularly in the diseased state, has always been very challenging and would have been impossible without proteomics. Neuroproteomic techniques have been extensively used for unraveling both dynamics and content of the proteome of our nervous system. This modern-day investigation and quantification of protein concentration and expression have given us a platform that enhances our knowledge on disease-associated processes and pathways modification and also leads to the identification of possible biomarkers that can he therapeutically targeted. With an increased interest in identifying and targeting possible hiomarkers, this article focuses on describing applications of the much discussed neuroproteomics, with a significant role in the disease pathogenesis of some very common neurological disorders. This article will collectively discuss the use and relevance of neuroproteomics in a range of neurological diseases, such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy, and psychiatric disorders. We have also attempted to present the current successes and failures of the neuroproteomics approach on the results obtained from different clinical studies that targeted hiomarkers associated with any particular neurological disorder.
引用
收藏
页码:1146 / 1163
页数:18
相关论文
共 172 条
[141]   Stoichiometric coupling of brain glucose metabolism and glutamatergic neuronal activity [J].
Sibson, NR ;
Dhankhar, A ;
Mason, GF ;
Rothman, DL ;
Behar, KL ;
Shulman, RG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (01) :316-321
[142]   Proteomic Approaches to Decipher Mechanisms Underlying Pathogenesis in Multiple Sclerosis Patients [J].
Singh, Vaibhav ;
Tripathi, Ajai ;
Dutta, Ranjan .
PROTEOMICS, 2019, 19 (16)
[143]   Proteomics Urine Analysis of Pregnant Women Suffering from Multiple Sclerosis [J].
Singh, Vaibhav ;
Stingl, Christoph ;
Stoop, Marcel P. ;
Zeneyedpour, Lona ;
Neuteboom, Rinze F. ;
Smitt, Peter Sillevis ;
Hintzen, Rogier Q. ;
Luider, Theo M. .
JOURNAL OF PROTEOME RESEARCH, 2015, 14 (05) :2065-2073
[144]   Proteomics technologies for biomarker discovery in multiple sclerosis [J].
Singh, Vaibhav ;
Hintzen, Rogier Q. ;
Luider, Theo M. ;
Stoop, Marcel P. .
JOURNAL OF NEUROIMMUNOLOGY, 2012, 248 (1-2) :40-47
[145]   Multiple sclerosis-related proteins identified in cerebrospinal fluid by advanced mass spectrometry [J].
Stoop, Marcel P. ;
Dekker, Lennard J. ;
Titulaer, Mark K. ;
Burgers, Peter C. ;
Smitt, Peter A. E. Sillevis ;
Luider, Theo M. ;
Hintzen, Rogier Q. .
PROTEOMICS, 2008, 8 (08) :1576-1585
[146]   Proteomic identification of nitrated brain proteins in amnestic mild cognitive impairment: a regional study [J].
Sultana, Rukhsana ;
Reed, Tanea ;
Perluigi, Marzia ;
Coccia, Rafaella ;
Pierce, William M. ;
Butterfield, D. Allan .
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2007, 11 (04) :839-851
[147]  
Sutandy F. R., 2013, J CELL PHYSL, V234, P382
[148]   Lower plasma apolipoprotein A1 levels are found in Parkinson's disease and associate with apolipoprotein A1 genotype [J].
Swanson, Christine R. ;
Li, Katherine ;
Unger, Travis L. ;
Gallagher, Michael D. ;
Van Deerlin, Vivianna M. ;
Agarwal, Pinky ;
Leverenz, James ;
Roberts, John ;
Samii, Ali ;
Gross, Rachel Goldmann ;
Hurtig, Howard ;
Rick, Jacqueline ;
Weintraub, Daniel ;
Trojanowski, John Q. ;
Zabetian, Cyrus ;
Chen-Plotkin, Alice S. .
MOVEMENT DISORDERS, 2015, 30 (06) :805-812
[149]   Antibody-mediated neutralization of myelin-associated EphrinB3 accelerates CNS remyelination [J].
Syed, Yasir A. ;
Zhao, Chao ;
Mahad, Don ;
Mobius, Wiebke ;
Altmann, Friedrich ;
Foss, Franziska ;
Sentuerk, Aycan ;
Acker-Palmer, Amparo ;
Lubec, Gert ;
Lilley, Kathryn ;
Franklin, Robin J. M. ;
Nave, Klaus-A. ;
Kotter, Mark R. N. .
ACTA NEUROPATHOLOGICA, 2016, 131 (02) :281-298
[150]   Identification of candidate biomarkers in converting and non-converting clinically isolated syndrome by proteomics analysis of cerebrospinal fluid [J].
Timirci-Kahraman, O. ;
Karaaslan, Z. ;
Tuzun, E. ;
Kurtuncu, M. ;
Baykal, A. T. ;
Gunduz, T. ;
Tuzuner, M. B. ;
Akgun, E. ;
Gurel, B. ;
Eraksoy, M. ;
Kucukali, Cem Ismail .
ACTA NEUROLOGICA BELGICA, 2019, 119 (01) :101-111